William Blair Analysts Increase Earnings Estimates for OVID

Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Analysts at William Blair lifted their Q2 2025 earnings per share (EPS) estimates for shares of Ovid Therapeutics in a report issued on Tuesday, November 12th. William Blair analyst S. Schram now anticipates that the company will earn $0.23 per share for the quarter, up from their previous estimate of $0.16. William Blair currently has a "Strong-Buy" rating on the stock. The consensus estimate for Ovid Therapeutics' current full-year earnings is ($0.49) per share.

Ovid Therapeutics (NASDAQ:OVID - Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.34. The firm had revenue of $0.17 million for the quarter, compared to analysts' expectations of $0.14 million. Ovid Therapeutics had a negative return on equity of 38.24% and a negative net margin of 5,142.56%.

Separately, HC Wainwright reiterated a "buy" rating and set a $3.00 target price on shares of Ovid Therapeutics in a research report on Monday, September 30th. Two investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $4.04.

Ovid Therapeutics Price Performance

Shares of NASDAQ:OVID traded down $0.07 during trading on Thursday, hitting $1.15. 135,980 shares of the company were exchanged, compared to its average volume of 390,903. Ovid Therapeutics has a 1-year low of $0.68 and a 1-year high of $4.10. The business's 50 day moving average is $1.16 and its 200-day moving average is $1.56. The company has a quick ratio of 5.73, a current ratio of 5.73 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $81.62 million, a P/E ratio of -2.60 and a beta of 0.41.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the business. Verition Fund Management LLC bought a new position in shares of Ovid Therapeutics in the third quarter worth $88,000. BNP Paribas Financial Markets raised its position in shares of Ovid Therapeutics by 4,128.7% in the third quarter. BNP Paribas Financial Markets now owns 220,401 shares of the company's stock worth $260,000 after buying an additional 215,189 shares in the last quarter. FMR LLC grew its position in Ovid Therapeutics by 1,907.4% during the third quarter. FMR LLC now owns 50,225 shares of the company's stock worth $59,000 after buying an additional 47,723 shares in the last quarter. GSA Capital Partners LLP increased its stake in Ovid Therapeutics by 118.0% in the 3rd quarter. GSA Capital Partners LLP now owns 260,509 shares of the company's stock worth $307,000 after acquiring an additional 141,002 shares during the last quarter. Finally, Assenagon Asset Management S.A. purchased a new stake in shares of Ovid Therapeutics in the 3rd quarter valued at about $102,000. 72.24% of the stock is owned by institutional investors.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies.